Integra LifeSciences (IART): amends credit agreement, issues $450,000,000 notes

What happened

• The filing says that on Oct 19, 2026 Integra LifeSciences entered into an amended and restated credit agreement with a syndicate of lenders and Bank of America, N.A., and completed a private unregistered offering of $450,000,000 aggregate principal amount of 9.500% senior secured notes due Nov 1, 2033.
• The filing says the Company also entered into an indenture dated Oct 19, 2026 with Truist Bank as trustee and notes collateral agent, and a ratification agreement with Bank of America, N.A.

Key details

• The new credit agreement makes up to $1,650,000,000 available through: a $600,000,000 senior secured revolving facility (five year maturity), a $600,000,000 senior secured term loan A facility (five year maturity) and a $450,000,000 senior secured term loan B facility (seven year maturity).
• Borrowings may be at Term SOFR plus a margin or an alternate base rate; the applicable Term SOFR margin is 4.25% for the Term Loan B Facility and initially 3.00% for the Revolving Facility and Term Loan A Facility (then 2.00% to 3.25% after the compliance certificate for the quarter ending Dec 31, 2026, based on consolidated total leverage ratio). The Company will pay an annual commitment fee of 0.20% to 0.35% (fixed at 0.30% until delivery of the Dec 31, 2026 compliance certificate).
• The $450,000,000 notes bear interest at 9.500% per year, payable semi-annually on May 1 and Nov 1 starting May 1, 2027, and mature Nov 1, 2033. The notes are senior secured obligations, guaranteed by substantially all domestic wholly-owned subsidiaries that guarantee the credit agreement and secured pari passu with borrowings under the credit agreement.
• In connection with the new credit agreement and the notes offering, the Company used proceeds to repay in full and terminate its existing credit agreement dated Mar 24, 2023 (which provided a $1,300,000,000 revolving facility and a $775,000,000 term loan). The filing says no early termination penalties were incurred.

Why it may matter

• Item 1.01 was reported: the filing covers entry into the amended and restated credit agreement, the ratification agreement and the indenture for the notes, and Item 1.02 reports termination of the Existing Credit Agreement. A filing does not show why the insider traded or why the company acted.